AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (previously presented) A pharmaceutical composition comprising activated protein C and a chelating agent.

2. (currently amended) The composition of claim 1 wherein the pharmaceutical composition is a lyophilized formulation.

3. (previously presented) The composition of claim 2 further comprising a bulking agent.

4. (previously presented) The composition of claim 3 wherein the bulking agent is selected from the group consisting of mannitol, trehalose, raffinose, sucrose, and mixtures thereof.

5. (previously presented) The composition of claim 4 further comprising a buffer selected from the group consisting of Tris-acetate, sodium citrate, sodium phosphate, and combinations thereof.

6. (previously presented) The composition of claim 5 further comprising a buffer such that upon reconstitution the formulation has a pH of about 5.5 to about 6.5.

7. (previously presented) The composition of claim 6 further comprising a salt.

8. (previously presented) The composition of claim 7 wherein the salt is selected from the group consisting of potassium chloride and sodium chloride.

9. (currently amended) The pharmaceutical composition according to Claim 2 ~~1~~, further comprising a diluent.

10. (canceled).

11. (previously presented) The composition of claim 9 wherein the diluent is a reconstitution diluent.

12. (previously presented) The composition of claim 9 wherein the diluent is an intravenous infusion solution.

13. (previously presented) The composition of claim 9 wherein the chelating agent is present in the diluent.

14. (currently amended) The composition of claim 9 ~~10~~ further comprising a bulking agent.

15. (previously presented) The composition of claim 14 wherein the bulking agent is selected from the group consisting of mannitol, trehalose, raffinose, sucrose, and mixtures thereof.

16. (previously presented) The composition of claim 15 further comprising a buffer selected from the group consisting of Tris-acetate, sodium citrate, sodium phosphate, and combinations thereof.

17. (previously presented) The composition of claim 16 further comprising a buffer such that upon reconstitution the formulation has a pH of about 5.5 to about 6.5.

18. (previously presented) The composition of claim 17 further comprising a salt.

19. (previously presented) The composition of claim 18 wherein the salt is selected from the group consisting of potassium chloride and sodium chloride.

20. (withdrawn) A process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C and a chelating agent.

21. (withdrawn) A process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C, a bulking agent, and a chelating agent.

22. (withdrawn) A process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C with a diluent containing a chelating agent.

23. (withdrawn) A process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C and a bulking agent with a diluent containing a chelating agent.

24. (currently amended) A method of treating a patient in need thereof which comprises administering to the patient the pharmaceutical composition of any one of claims 1 through 9 and 11 through 19.

25. (canceled).